Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of our study is to determine the safety and efficacy of the combination of
erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with
neurological diseases. To be specific, our clinical study is expected that the combination
injection of EPO and G-CSF shows neurotrophic and neuroprotective effects by facilitating
endogenous repair process in patients with neurological diseases including stroke, cerebral
palsy, or atypical parkinsonism. Therefore, we will apply our original treatment technique in
patients with neurological diseases, which is expected to overcome current ethical and
technical limitations of less evidenced functional recovery, hematological changes, and side
effects. Eventually, We will establish a comprehensive clinical background about neurotrophic
and neuroprotective effects of this hematopoietic growth factors therapy.